From WBA’s post this morning ‘Currently, Brickell Biotech’s Ecclock (sofpironium bromide) is the only anticholinergic pipeline agent in Phase III development. Despite having superior efficacy to Qbrexza, Ecclock gel does not offer a better delivery method.’
I reckon BOT thinks Permetrex is the delivery method that will set it apart from the competition.
From WBA’s post this morning ‘Currently, Brickell Biotech’s...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $563.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 33.0¢ | 31.0¢ | $1.731M | 5.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 606129 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 92444 | 5 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |